| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -15,623,518 | -10,339,145 |
| Depreciation and amortization | 65,805 | 42,988 |
| Stock-based compensation expense | 1,401,528 | 941,523 |
| Other non-cash items | -793,744 | -782,880 |
| Prepaid expenses and other current assets | 386,545 | 1,252,940 |
| Long term deposit and other noncurrent assets | -2,319 | -1,778 |
| Accounts payable and other current liabilities | 316,652 | 1,265,791 |
| Defined benefit pension plan | -103,702 | -68,395 |
| Deferred grant income | -313,228 | -294,989 |
| Total changes in operating assets and liabilities | 484,504 | 348,755 |
| Cash used in operating activities | -13,846,945 | -8,920,509 |
| Net proceeds from issuance of shares in atm offering (note 14) | 4,910,240 | 4,910,240 |
| Net proceeds from issuance of shares and warrants in public offering (note 14) | 7,411,554 | - |
| Net proceeds from the exercise of warrants (note 14) | 41,745 | - |
| Payments of offering costs (note 14) | 395,478 | - |
| Payments of current portion of long-term debt (note 12) | 71,476 | 46,480 |
| Cash provided by financing activities | 11,896,585 | 4,863,760 |
| Effect of exchange rate changes | 376,272 | 369,605 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -1,574,088 | -3,687,144 |
| Cash and cash equivalents at beginning of period | 10,417,558 | - |
| Cash and cash equivalents at end of period | 8,843,470 | - |
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)